1. symptom treatment Beta2-sympathomimetics are derived from epinephrine. They selectively stimulate the adrenergic β2-receptors of bronchial muscles and thus have a bronchospasmolytic effect. For rapid symptom relief, fast-acting agents are usually administered by inhalation, for example, with a metered-dose inhaler or a powder inhaler. They should be used only when needed. An increase in administration … Antiasthmatics
Products Beta2-sympathomimetics are usually commercially available as inhalation preparations (powders, solutions) administered with an inhaler, for example, metered-dose inhaler, diskus, Respimat, Breezhaler, or Ellipta. There are few drugs on the market that can be given perorally. Structure and properties Beta2-sympathomimetics are structurally related to the natural ligands epinephrine and norepinephrine. They may exist as racemates … Beta2-Sympathomimetics
Products Sympathomimetics are commercially available, for example, in the form of tablets, capsules, granules, injectable solutions, eye drops, and nasal sprays. Structure and properties Sympathomimetics are structurally derived from the natural neurotransmitters epinephrine and norepinephrine. Effects Sympathomimetics have sympathomimetic properties, meaning that they promote the effects of the sympathetic nervous system, a portion of the … Sympathomimetics
Symptoms Possible symptoms of chronic obstructive pulmonary disease (COPD) include a chronic cough, mucus production, sputum, shortness of breath, chest tightness, breath sounds, lack of energy, and sleep disturbances. The symptoms often worsen with physical exertion. An acute worsening of chronic symptoms is referred to as an exacerbation. In addition, numerous systemic and extrapulmonary concomitant … Chronic Obstructive Pulmonary Disease
Products Umeclidinium bromide is commercially available as a powder for inhalation as a monopreparation (Incruse Ellipta) and as a fixed combination with vilanterol (Anoro Ellipta, LAMA–LABA combination). It was approved in many countries in 2014. In 2017, a combination of umeclidinium bromide, fluticasone furoate, and vilanterol was released in the EU (Trelegy Ellipta), and in … Umeclidinium Bromide
Products The active ingredient fluticasone has been approved in many countries since 1994 and is included in numerous drugs: Powder inhalers (Arnuity Ellipta, Seretide + salmeterol, Relvar Ellipta + vilanterol, Trelegy Ellipta + vilanterol + umeclidinium bromide). Metered dose inhalers (Axotide, Seretide + salmeterol, Flutiform + formoterol). Nasal sprays (Avamys, Nasofan, Dymista + azelastine). Nasal … Fluticasone
Products Vilanterol is commercially available as a fixed combination with fluticasone furoate in powder inhaler form (Relvar Ellipta / Breo Ellipta). It was approved in the US and EU in 2013 and in many countries in 2014. The fixed combination with umeclidinium bromide (Anoro Ellipta) was also registered in many countries in 2014. In 2017, … Vilanterol
Products Dermocorticoids are commercially available in the form of creams, ointments, lotions, gels, pastes, foams, scalp applications, shampoos, and solutions, among others. Numerous drugs are available, including many combination preparations. Hydrocortisone was the first active ingredient to be used in the 1950s. Today, dermocorticoids are among the most important drugs in dermatology. Effects Glucocorticoids have … Topical Glucocorticoids: Dermocorticoids